A class action lawsuit has been filed against Doximity, Inc. alleging securities fraud. The complaint claims Doximity overstated its Newsfeed's revenue impact, was losing market share to competitors, and misrepresented its advertising practices. Investors who purchased Doximity securities between August 8, 2024 and May 13, 2026 may be eligible to join the case, with a lead plaintiff deadline of November 16, 2026.

Doximity announced an extension of its 13-year partnership with U.S. News & World Report, continuing to provide physician data for Doctor Finder, Patient Connect appointment-booking tools, and Expert Opinion surveys for hospital rankings. The partnership leverages Doximity's network of 3+ million medical professionals to connect patients with healthcare providers. Despite the news, DOCS stock declined 2.1% following the announcement and is down 32.4% year-to-date.

Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.

Rosen Law Firm reminds investors who purchased Doximity, Inc. (DOCS) shares between August 8, 2024 and May 13, 2026 of the November 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges Doximity misrepresented the impact of its news feed feature on revenue growth while losing market share to competitors with better pricing and user engagement models.

Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by directors and officers of Sprout Social, Inc. The firm is encouraging shareholders to contact them regarding their rights. Additional securities class action investigations are also underway for Doximity, Inc. and UWM Holdings Corporation.

Rosen Law Firm is urging investors who purchased Doximity common stock between August 8, 2024 and May 13, 2026 to join a securities class action lawsuit before the November 16, 2026 lead plaintiff deadline. The lawsuit alleges that Doximity overstated the revenue impact of its Newsfeed feature, lost market share to competitors, and relied on less effective engagement tactics, causing investor damages when the truth emerged.

Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Better Home & Finance (BETR), Doximity (DOCS), Baidu (BIDU), and UWM Holdings (UWMC). The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their business operations. Investors have until specified deadlines in October and November 2026 to file lead plaintiff motions.

Doximity (DOCS) closed at $28.58, up 2.33%, outperforming the S&P 500's 0.66% gain. The stock has gained 6% over the past month despite the Medical sector declining 3.74%. Upcoming earnings are expected to show an EPS of $0.34 (down 24.44% YoY) with revenue of $170.66 million (up 1.27% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 20.93, trading at a discount to its industry average of 31.16.

A class action securities fraud lawsuit has been filed against Doximity, Inc. for allegedly making materially false statements about its business operations. The company failed to disclose that it overstated its Newsfeed's revenue impact, was losing market share to competitors, and relied on less effective advertising tactics. Doximity's stock declined significantly following three disappointing earnings announcements between November 2025 and May 2026, with the company missing guidance and projecting slower growth. The deadline to file a lead plaintiff motion is November 16, 2026.

A class action lawsuit has been filed against Doximity, Inc. alleging securities fraud. The complaint claims Doximity made false statements about its Newsfeed's revenue impact, overstated market position, and misrepresented advertising practices. The lawsuit covers investors who purchased Doximity securities between August 8, 2024 and May 13, 2026. The lead plaintiff deadline is November 16, 2026.

Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth.

Rosen Law Firm is reminding investors who purchased Doximity common stock between August 8, 2024 and May 13, 2026 to join a securities class action lawsuit before the November 16, 2026 lead plaintiff deadline. The lawsuit alleges that Doximity overstated the revenue impact of its Newsfeed feature and lost market share to competitors while relying on less effective advertising methods.